326 related articles for article (PubMed ID: 25230992)
1. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C
Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992
[TBL] [Abstract][Full Text] [Related]
2. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors.
Favot L; Keravis T; Holl V; Le Bec A; Lugnier C
Thromb Haemost; 2003 Aug; 90(2):334-43. PubMed ID: 12888882
[TBL] [Abstract][Full Text] [Related]
3. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4.
Favot L; Keravis T; Lugnier C
Thromb Haemost; 2004 Sep; 92(3):634-45. PubMed ID: 15351862
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1.
Abusnina A; Keravis T; Yougbaré I; Bronner C; Lugnier C
Mol Nutr Food Res; 2011 Nov; 55(11):1677-89. PubMed ID: 22045655
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of phosphodiesterases PDE2, PDE3, and PDE4 do not increase the sinoatrial tachycardia of noradrenaline and prostaglandin PGE₁ in mice.
Galindo-Tovar A; Vargas ML; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 2016 Feb; 389(2):177-86. PubMed ID: 26531832
[TBL] [Abstract][Full Text] [Related]
8. Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.
Hiramoto K; Murata T; Shimizu K; Morita H; Inui M; Manganiello VC; Tagawa T; Arai N
Cell Signal; 2014 Sep; 26(9):1807-17. PubMed ID: 24705027
[TBL] [Abstract][Full Text] [Related]
9. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel.
Lugnier C; Keravis T; Eckly-Michel A
J Physiol Pharmacol; 1999 Dec; 50(4):639-52. PubMed ID: 10639014
[TBL] [Abstract][Full Text] [Related]
10. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes.
Keravis T; Komas N; Lugnier C
J Vasc Res; 2000; 37(4):235-49. PubMed ID: 10965223
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2.
Diebold I; Djordjevic T; Petry A; Hatzelmann A; Tenor H; Hess J; Görlach A
Circ Res; 2009 May; 104(10):1169-77. PubMed ID: 19390057
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes.
Mika D; Bobin P; Pomérance M; Lechêne P; Westenbroek RE; Catterall WA; Vandecasteele G; Leroy J; Fischmeister R
Cardiovasc Res; 2013 Nov; 100(2):336-46. PubMed ID: 23933582
[TBL] [Abstract][Full Text] [Related]
16. Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.
Campos-Toimil M; Keravis T; Orallo F; Takeda K; Lugnier C
Br J Pharmacol; 2008 May; 154(1):82-92. PubMed ID: 18311187
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
Kyoi T; Oka M; Noda K; Ukai Y
Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
